402 Spam-Free Article(s) Found
Symbol Name Last Close Mkt Cap DailyStocks'
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Monday’s Close
JAZZ Jazz Pharmaceuticals plc $161.01 $9.73B Downtrend
Article Searches
Clippers vs. Jazz: How the teams match up for their playoff series http://www.latimes.com/la-sp-clippers-jazz-matchups-20170414-story.html Apr 14, 2017 -

Since February 2012, the Clippers have been the rulers of the regular-season series against the Utah Jazz.

Surely then, it was suggested to Chris Paul, the Clippers must be brimming with confidence for their first-round playoff matchup against the Jazz that starts Saturday night with Game 1 at...

Los Angeles Clippers seek to write a new chapter, turn around their playoff misfortunes http://www.latimes.com/la-sp-clippers-jazz-20170413-story.html Apr 13, 2017 -

On the one hand, Clippers players admit they feel the weight of past playoff failures — to a degree.

On the other hand, Coach Doc Rivers suggests that it’s a narrative perpetuated by the media.

Wherever one stands on the issue, there are basic truths that cannot be ignored.

It’s a fact that the...

'Vince Giordano: There's a Future in the Past' shows it's hard work keeping old-time jazz alive http://www.latimes.com/la-et-mn-capsule-vince-giordano-review-20170413-story.html Apr 13, 2017 -

Unless you’re a jazz aficionado or a denizen of New York’s classier nightclubs and society functions, you may not be familiar with the work of Vince Giordano — even though the bandleader and music archivist has been one of the most in-demand early 20th century Americana revivalists for decades.

Clippers clinch No. 4 seed with victory over Sacramento Kings 115-95 http://www.latimes.com/la-sp-clippers-kings-20170412-story.html Apr 12, 2017 -

DeAndre Jordan had 18 points and 17 rebounds, and the Clippers defeated the Sacramento Kings 115-95 on Wednesday night to clinch the No. 4 seed in the West and home-court advantage in the playoffs.

The Clippers and Utah Jazz will meet in the first round starting this weekend. The teams finished...

Clippers ready for the Jazz with previous playoff failures in the back of their minds http://www.latimes.com/la-sp-clippers-report-20170412-story.html Apr 12, 2017 -

The Clippers have their playoff burdens to bear, their inability to get past a certain threshold constantly weighing on them.

But having reached the playoffs for the sixth consecutive season brings the Clippers new hope that they can get past the second round for the first time in franchise history.

What's Next For Jazz Pharmaceuticals? https://seekingalpha.com/article/4061439-next-jazz-pharmaceuticals?source=feed_tag_editors_picks Apr 10, 2017 - Vyxeos (CPX-351) has shown stark improvement for patients with AML.JAZZ has moved along to the final stages of development.Consider the cost-benefit of CPX-351 before considering an investment at this
Jazz Pharma (JAZZ) Up 7.6% Since Earnings Report: Can It Continue? http://www.zacks.com/stock/news/254769/jazz-pharma-jazz-up-76-since-earnings-report-can-it-continue?cid=CS-ZC-FT-254769 Mar 31, 2017 - Jazz Pharma (JAZZ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Jazz Pharma out-licenses Defitelio and Vyxeos in Japan https://seekingalpha.com/news/3254382-jazz-pharma-licenses-defitelio-vyxeos-japan?source=feed_news_all Mar 30, 2017 - Jazz Pharmaceuticals (NASDAQ:JAZZ) inks an exclusive license agreement with Nippon Shinyaku Co., Ltd. to develop and commercialize Defitelio (defibrotide sodium) and Vyxeos (cytarabine and daunorubici
Jazz Pharma loses challenge to Xyrem patent covering distribution system; shares slip 1% http://seekingalpha.com/news/3252824-jazz-pharma-loses-challenge-xyrem-patent-covering-distribution-system-shares-slip-1-percent?source=feed_news_all Mar 22, 2017 - In an inter partes review proceeding, the Patent Trial and Appeal Board (PTAB) rules that three claims of Jazz Pharmaceuticals' (JAZZ -0.9%) U.S. Patent No. 8,731,963 is invalid as obvious. Th
Jazz Sleep Disorder Drug Positive in Phase III Studies http://www.zacks.com/stock/news/253568/jazz-sleep-disorder-drug-positive-in-phase-iii-studies?cid=CS-ZC-FT-253568 Mar 21, 2017 - Jazz Pharmaceuticals plc (JAZZ) recently announced positive efficacy results from two phase III studies evaluating the safety and efficacy of its lead pipeline candidate JZP-110 for the treatment of excessive sleepiness.

Pages: 1...3435363738394041

<<<Page 39>